Background and Aims Binge eating disorder (BED) is correlated with substance use. This study aimed to estimate the life‐time prevalence of alcohol use disorder (AUD) among individuals with non‐compensatory binge eating and determine whether their life‐time prevalence of AUD is higher than in non‐bingeing controls. Design A systematic search of databases (PubMed, Embase and Web of Science) for studies of adults diagnosed with BED or a related behavior that also reported the life‐time prevalence of AUD was conducted. The Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) protocol was followed. The protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO). Setting Studies originating in Canada, Sweden, the United Kingdom and the United States. Participants Eighteen studies meeting the inclusion criteria were found, representing 69 233 individuals. Measurements Life‐time prevalence of AUD among individuals with binge eating disorder and their life‐time relative risk of AUD compared with individuals without this disorder. Results The pooled life‐time prevalence of AUD in individuals with binge eating disorder was 19.9% [95% confidence interval (CI) = 13.7–27.9]. The risk of life‐time AUD incidence among individuals with binge eating disorder was more than 1.5 times higher than controls (relative risk = 1.59, 95% CI = 1.41–1.79). Life‐time AUD prevalence was higher in community samples than in clinical samples (27.45 versus 14.45%, P = 0.041) and in studies with a lower proportion of women (β = −2.2773, P = 0.044). Conclusions Life‐time alcohol use disorder appears to be more prevalent with binge eating disorder than among those without.
The development of SU-induced hypothyroidism, hypertension, neutropenia and edema was a significant predictive and prognostic factor.
The World Marrow Donor Organization recommends original granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in healthy unrelated hematopoietic stem cell donors. We report the comparison of a biosimilar G-CSF (Zarzio) with two original G-CSFs (filgrastim and lenograstim) in mobilization in unrelated donors. We included data of 313 consecutive donors who were mobilized during the period from October 2014 to March 2016 at the Medical University of Warsaw. The primary endpoints of this study were the efficiency of CD34+ cell mobilization to the circulation and results of the first apheresis. The mean daily dose of G-CSF was 9.1 μg/kg for lenograstim, 9.8 μg/kg for biosimilar filgrastim, and 9.3 μg/kg for filgrastim (p < 0.001). The mean CD34+ cell number per microliter in the blood before the first apheresis was 111 for lenograstim, 119 for biosimilar filgrastim, and 124 for filgrastim (p = 0.354); the mean difference was even less significant when comparing CD34+ number per dose of G-CSF per kilogram (p = 0.787). Target doses of CD34+ cells were reached with one apheresis in 87% donors mobilized with lenograstim and in 93% donors mobilized with original and biosimilar filgrastim (p = 0.005). The mobilized apheresis outcomes (mean number of CD34+ cells/kg of donor collected during the first apheresis) was similar with lenograstim, biosimilar filgrastim, and filgrastim: 6.2 × 106, 7.6 × 106, and 7.3 × 106, respectively, p = 0.06. There was no mobilization failure in any of the donors. Biosimilar G-CSF is as effective in the mobilization of hematopoietic stem cells in unrelated donors as original G-CSFs. Small and clinically irrelevant differences seen in the study can be attributed to differences in G-CSF dose and collection-related factors. Active safety surveillance concurrent to clinical use and reporting to donor outcome registry (e.g., EBMT donor outcome registry or WMDA SEAR/SPEAR) might help to evaluate the possible short- and long-term complications of biosimilar G-CSF.
Przegląd literatury badań z zakresu regulacji emocji w zespole kompulsywnego objadania się, (BED) opublikowanej w języku polskim i angielskim w latach 1990 - 2020. BED może być rozumiane jako impulsywne i kompulsywne zaburzenie, związane ze zmienioną wrażliwością w aktywacji układu nagrody oraz stronniczością uwagi skierowaną na jedzenie. Wyniki badań neuroobrazowych dowodzą istnienia zmian w obwodach korowo-prążkowiowych u osób z BED, podobnych do tych obserwowanych w uzależnieniu od substancji psychoaktywnych, m.in. zmieniona funkcja kory przedczołowej, okołooczodołowej, prążkowia oraz wyspy. Negatywne emocje oraz deficyty w ich regulacji odgrywają znaczącą rolę w BED. Szczególnie istotne w tym zaburzeniu wydają się: gniew, lęk oraz smutek. Badania zidentyfikowały wzrost negatywnych emocji, poprzedzający epizody objadania się. Jednakże wciąż w literaturze badań brakuje konsensusu czy omawiane epizody redukują negatywny afekt. Osoby z BED częściej wykorzystują nieadaptacyjne strategie regulacji emocji, takie jak ruminacja oraz tłumienie negatywnych uczuć. Rzadziej natomiast adaptacyjne, takie jak poznawcza reinterpretacja. Implikacje kliniczne, poza farmakoterapią, uwzględniają wysoką skuteczność wzmocnionej terapii poznawczo-behawioralnej (CBT-E), terapii dialektyczno-behawioralnej (DBT) oraz psychoterapii psychodynamicznej w leczeniu zaburzonej regulacji emocji w BED. Dalsze badania, z wyszczególnieniem obiecującej metody Ecological momentary assessment (EMA), powinny skupiać się na zmianach emocji związanych z cyklem objadania się oraz identyfikacji czynników wzmacniających.
Background and Objectives Many consider volunteer blood donors as ideal candidates for unrelated haematopoietic progenitor cell (HPC) donation. However, frequent blood donations could influence the results of HPC mobilization. To our best knowledge, there are no data on the possible impact of repeated blood donation on efficiency of subsequent HPC mobilization by granulocyte colony‐stimulating factor (G‐CSF). Materials and Methods We compared outcomes of HPC mobilization in unrelated donors with and without a history of blood donation. We conducted a prospective study on 287 consecutive donors admitted to the Department of Hematology since January 2016. The final analysis included 153 donors who agreed to take part in the study and had undergone stem cell mobilization with G‐CSF. Results History of blood donations prior to haematopoietic stem cell mobilization with G‐CSF does not have a significant impact on the number of collected CD34+ cells in the first leucocytapheresis (516.2 x 106 (170–1148) in blood donors vs 490.5 x 106 (101–1154) in non‐donors) (P = 0.32). In all donors, in this study mobilization of HPC was successful: 87.5% of blood donors and 85.6% of non‐donors collected the required cell number in a single apheresis. In blood donors, a higher number of blood donations within 2 and 5 years prior to HPC mobilization correlated significantly with successful donation within one leucocytapheresis (P = 0.014 and P = 0.024, respectively). Conclusion Multiple blood donations do not significantly influence the outcome of HPC collection in unrelated donors. Blood donors and non‐donors have similar results of HPC collection, so there is no reason to favour either group.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.